What is Joinn Laboratories (China) Co Cash Flow from Investing?
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
For the
three
months ended in Mar. 2024, Joinn Laboratories (China) Cospent¥59 Mil on purchasing property, plant, equipment.
It gained¥0 Mil from selling property, plant, and equipment.
It spent¥0 Mil on purchasing business.
It gained¥0 Mil from selling business.
It spent¥120 Mil on purchasing investments.
It gained¥102 Mil from selling investments.
It paid¥0Mil for net Intangibles purchase and sale.
And it received¥9 Mil from other investing activities.
In all, Joinn Laboratories (China) Cospent¥68 Mil on investment activities in financial market and operating subsidiaries for the
three
months ended in Mar. 2024.
Joinn Laboratories (China) Co Cash Flow from Investing Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Joinn Laboratories (China) Co Cash Flow from Investing Chart
Joinn Laboratories (China) Co Cash Flow from Investing Calculation
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).
Likewise, if a company buys another company for cash, this will reduce their cash position.
Joinn Laboratories (China) Co's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:
Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-489 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joinn Laboratories (China) Co (SHSE:603127) Cash Flow from Investing Explanation
Joinn Laboratories (China) Co's purchase of property, plant, equipment for the
three
months ended in Mar. 2024 was ¥-59 Mil. It means Joinn Laboratories (China) Co spent ¥59 Mil on purchasing property, plant, equipment.
In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.
In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Joinn Laboratories (China) Co's sale of property, plant, equipment for the
three
months ended in Mar. 2024 was ¥0 Mil. It means Joinn Laboratories (China) Co gained ¥0 Mil from selling property, plant, and equipment.
3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.
Joinn Laboratories (China) Co's purchase of business for the
three
months ended in Mar. 2024 was ¥0 Mil. It means Joinn Laboratories (China) Co spent ¥0 Mil on purchasing business.
4. Sale Of Business:
Sale of business indicates the amount gained from selling business.
Joinn Laboratories (China) Co's sale of business for the
three
months ended in Mar. 2024 was ¥0 Mil. It means Joinn Laboratories (China) Co gained ¥0 Mil from selling business.
5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.
Joinn Laboratories (China) Co's purchase of investment for the
three
months ended in Mar. 2024 was ¥-120 Mil. It means Joinn Laboratories (China) Co spent {stock_data.stock.currency_symbol}}120 Mil on purchasing investments.
6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.
Joinn Laboratories (China) Co's sale of investment for the
three
months ended in Mar. 2024 was ¥102 Mil. It means Joinn Laboratories (China) Co gained ¥102 Mil from selling investments.
7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.
Joinn Laboratories (China) Co's net Intangibles purchase and sale for the
three
months ended in Mar. 2024 was ¥0 Mil.
It means Joinn Laboratories (China) Co paid ¥0 Mil for net Intangibles purchase and sale.
8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.
Joinn Laboratories (China) Co's cash from discontinued investing activities for the
three
months ended in Mar. 2024 was 0 Mil.
It means Joinn Laboratories (China) Co paid ¥0 Mil for discontinued investing activities.
9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.
Joinn Laboratories (China) Co's cash from other investing activities for the
three
months ended in Mar. 2024 was ¥9 Mil.
It means Joinn Laboratories (China) Co received ¥9 Mil from other investing activities.
Joinn Laboratories (China) Co Cash Flow from Investing Related Terms
Thank you for viewing the detailed overview of Joinn Laboratories (China) Co's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.
Joinn Laboratories (China) Co (SHSE:603127) Business Description
Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non- Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SHSE:603127 has been successfully added to your 